Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 9/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005982 | 0.91 | VEGFA (0.59) | VEGFAEGLN1GAAL3MBTL1ALDH1A1 | |
| SCHEMBL28572935 | 0.89 | VEGFA (0.76) | VEGFAEGLN1MAPK1 | |
| SCHEMBL17005895 | 0.89 | VEGFA (0.66) | VEGFAEGLN1CYP2D6FAAHGAA | |
| SCHEMBL17005945 | 0.88 | VEGFA (0.62) | VEGFAEGLN1CYP2D6FAAHALDH1A1 | |
| SCHEMBL17005882 | 0.88 | VEGFA (0.59) | VEGFAEGLN1CYP2D6FAAHGAA | |
| SCHEMBL17005967 | 0.88 | VEGFA (0.59) | VEGFAEGLN1FAAHALDH1A1KDM4E | |
| SCHEMBL17005911 | 0.87 | VEGFA (0.56) | VEGFAEGLN1CYP2D6FAAHALDH1A1 | |
| SCHEMBL1770477 | 0.87 | VEGFA (0.66) | VEGFAEGLN1GAAL3MBTL1ALDH1A1 | |
| SCHEMBL17005907 | 0.86 | VEGFA (0.52) | VEGFAEGLN1CYP2D6FAAHALDH1A1 | |
| SCHEMBL17005839 | 0.86 | VEGFA (0.60) | VEGFAEGLN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106232120-B | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones | 爱尔皮奥治疗有限公司 | 2021-01-08 | — | — | CN | disclosed |
| EP-3107542-B1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3107542-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | Aerpio Therapeutics, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| US-9388135-B2 | Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones | AERPIO THERAPEUTICS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| WO-2015126860-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | AERPIO THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232425-A1 | PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES | CYP4B1, CYP8B1, HPD | VEGFA 4681/4885EGLN1 102/4885CYP2D6 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.